Member Info for Ghia

Same buyer using multiple parties to avoid TR1's?

Because the demand for testing is huge and GDR and AVCT both have promising tests that will cater for different use cases in that market.

Chrishar,

Welcome to the biotech sector! Notoriously difficult to place value on research until results are published and verified.

Hi Chrishar,

All the information you seek can be found in the RNS’s please help yourself. Once you have digested that info come back and I’ll be happy to answer any questions you may have.

I would suggest that text was talking in more general terms about previous trials for COPD rather than specifics about the current trial.

I doubt we have dosed 100patients yet.

Well said Sharesting.

Plenty of good reading, research and relaxing to be done over the weekend.

Everyone stay safe and let’s see what next week brings.

Sharesting Normally anyone who has to state that they are a large investor on a board usually is full of hot air. However I’ve picked up on a few of your reactions to my posts and I believe you, I think we may share a similar source of information.

I hope you have been hoovering up a fair few of these.

My conservative estimate is 70 odd patients dosed. Just going off when first dosages have been notified by new sites.

Might end up with a chunk of AZN shares for our patience that would be nice.

They have the funding to start manufacturing do you think they have been as bold as to start stockpiling?

Old info but worth a repost.

We are supported by NIHR

"NIHR supports COVID-19 trial looking to reduce symptoms and upregulate lung antiviral defences"
https://www.nihr.ac.uk/news/nihr-supports-covid-19-trial-looking-to-reduce-symptoms-and-upregulate-lung-antiviral-defences/24484

This link shows the 10 most probable sites involved in our trial.

https://www.nihr.ac.uk/partners-and-industry/industry/collaborate-with-us/respiratory-trc.htm

Thank You. Are you a holder?

Looks like I might be about to top up again getting dangerously close to my first limit buy.

Don't forget we have a huge head start here since the drug was already in the middle of phase 2 trials for other related illnesses.

Our only competition short term are drugs that are already in existence of which in my opinion nothing shows as much promise as our treatment.

There will also be a market for this drug in COPD and Asthma after this pandemic has passed.

Let the science do the talking here, lots of other touted treatments are starting to get bad press from results based on statistically flawed studies or significant side effects.

iamrich I assume you are talking about phase 3 trials there? Company publicly states on their website they are not offering the drug outside of the phase 2 trial currently.

I agree if successful phase 2 data this will get rolled out far and wide whilst phase 3 is done in the background.

Lets hope we beat the big boys to it.

https://www.ft.com/content/6b73b1ba-b14b-4cda-a416-28cf52fc6d81

I'm not sure it will be black and white.

Obviously we are all hoping for clear cut results that prove the drug is an effective treatment for Covid-19.

Worst case is it's found to have zero impact.

However we have the knowledge from previous trials that it is an effective treatment for similar respiratory problems. Personally I think that reduces the risk significantly of news stating no benefit found.

So in my opinion the news will range from: Some benefit to significant benefit.

I think it's safe to say now that most of the placement shares have been or are being offloaded since Lansdowne are the only TR1 showing they added £4mil.

Is the TR1 deadline 3days or 5days?

This company is the real deal, everything is being done to the letter and to the highest standard. When we get news either way the data will be backed up by science and if good will provide a solid foundation.

We can see from tehir website there is interest in the product from outside the trial.

"Access to SNG001 to treat individuals outside clinical trials
On the 18th March Synairgen announced its plans to initiate a pilot clinical trial of SNG001 in COVID-19 patients. The trial will provide data on the efficacy of inhaled interferon beta in the treatment of ambulatory and hospitalised patients infected with SARS-CoV-2. Since the announcement, we have received a number of requests for SNG001 supplies to treat individuals outside the trial. As SNG001 is an experimental drug, untested as to safety and efficacy in this patient group, we regret that we are unable to fulfil any such request at this time. Synairgen’s team is working very hard to establish these measures in a well-controlled environment as quickly as possible."